If medication has stopped controlling your facial pain and a neurologist has raised the idea of surgery, you may have heard the term “microvascular decompression” — a procedure done through a small opening in the skull behind the ear, called a retrosigmoid craniotomy.
Key Points
- A retrosigmoid craniotomy is a neurosurgical approach used, among other indications, for microvascular decompression (MVD) in trigeminal neuralgia that has not responded to medication.
- A small 2026 prospective study (n=10, PMID 42617496) tested a patient-specific 3D-printed guide to help surgeons locate the transverse-sigmoid sinus junction and plan burrholes before this type of craniotomy; the reported 100% localization accuracy is based on only 10 cases and should be read as preliminary.
- This study is neurosurgical, not a dental or orofacial pain intervention — its relevance here is as background for patients being referred for surgical evaluation.
- A single-center, long-term retrospective study of 150 post-craniotomy patients reported a substantial proportion developing chronic craniomandibular and head/neck pain after surgery; this is one study, not an established population-level estimate, but is relevant to post-surgical follow-up planning.
- Surgical decisions for trigeminal neuralgia are made by neurosurgery; this practice’s role is diagnosis, conservative management, and coordinated referral.
What is a retrosigmoid craniotomy, and why does it come up in facial pain care?
A craniotomy is an opening made in the skull to allow access to structures inside it. The retrosigmoid approach enters behind the sigmoid sinus, a venous channel at the back of the skull, and is one of the standard routes neurosurgeons use to reach the trigeminal nerve at the base of the brain. It is used, among other applications, for microvascular decompression, a procedure in which a blood vessel found to be compressing the trigeminal nerve is repositioned to relieve compression-related facial pain.
This practice does not perform this surgery. It becomes relevant when a patient with trigeminal neuralgia — sudden, severe, shock-like facial pain along one or more branches of the trigeminal nerve — has not achieved adequate control with first-line medication (typically carbamazepine or oxcarbazepine) and is being considered for neurosurgical referral.
The new study (PMID 42617496) describes a 3D-printed surgical guide designed to help the neurosurgeon locate two landmarks before opening the skull: the planned burrhole sites and the transverse-sigmoid sinus junction, a venous structure that must be avoided during the approach. In a prospective cohort of 10 patients — two of whom had trigeminal neuralgia — the guide achieved accurate localization in all 10 cases, with a mean setup time of 3.9 minutes. This sample size is too small to establish a reliable accuracy rate; a single additional failure in a larger cohort would substantially change the reported figure. One elderly patient in the cohort experienced an intraoperative injury to the transverse sinus. Transverse sinus injury is a reported complication of retrosigmoid craniotomy in the neurosurgical literature; because this study had no comparison group of patients treated without the guide, it cannot determine whether guide use affected the likelihood of this event, and age or other patient-specific factors may also be relevant.
How is trigeminal neuralgia diagnosed?
Diagnosis is clinical, based on the characteristic pain pattern (brief, electric-shock-like episodes, often triggered by light touch, chewing, or talking, following the distribution of one or more trigeminal branches) and a neurological examination to rule out other causes. MRI is typically obtained to look for structural causes, including neurovascular contact with the trigeminal nerve accompanied by morphological change (such as nerve displacement or atrophy), which is consistent with vascular compression, or, less commonly, a demyelinating lesion or mass. Incidental neurovascular contact without accompanying morphological change is common in asymptomatic individuals and, per current classification criteria, is not by itself sufficient to establish a diagnosis of classical trigeminal neuralgia or to indicate surgical candidacy. Dental and TMJ evaluation is often part of the diagnostic pathway, since trigeminal neuralgia can be mistaken for dental or temporomandibular pain, and the reverse is also true.
Which treatment is right for me?
| Option | What the evidence shows | Best suited to |
|---|---|---|
| Anticonvulsant medication (carbamazepine, oxcarbazepine) | First-line therapy; effective for most patients initially | Newly diagnosed or medication-responsive trigeminal neuralgia |
| Microvascular decompression (via retrosigmoid craniotomy) | Established neurosurgical option for medication-refractory cases with imaging evidence of vascular compression (neurovascular contact with morphological change, not incidental contact alone); guide technology (PMID 42617496) is an early-stage tool to improve precision, not a treatment itself | Patients who have failed or cannot tolerate medication, with imaging evidence of vascular compression rather than incidental contact |
| Percutaneous or radiosurgical procedures (e.g., gamma knife, balloon compression) | Alternatives to open surgery, generally with different risk/benefit and recurrence profiles; not addressed by this study | Patients who are poor surgical candidates or prefer a less invasive option |
| Conservative/dental evaluation | Rules out or addresses overlapping TMJ or dental sources of facial pain | All patients at initial presentation |
The decision between medication, surgery, and other procedural options is made jointly by the patient, neurologist, and neurosurgeon, based on diagnosis certainty, imaging findings, medication response, and patient preference. This practice’s role is limited to diagnosis, exclusion of dental/TMJ contributors, and coordinated referral.
What the new research adds — and its limits
The surgical guide study is a small, early-stage feasibility report. Its sample size (n=10, with only two trigeminal neuralgia cases) is too small to establish safety or efficacy conclusions, there was no comparison group of patients treated without the guide, and one documented adverse event (transverse sinus injury, in an elderly patient) occurred in the cohort. The reported measures — localization accuracy and setup time — describe technical feasibility of the guide, not patient pain outcomes. This is standard for early device-development literature and does not yet support broader claims about surgical safety or outcomes.
A separate consideration for anyone referred for cranial surgery is post-surgical craniomandibular pain. One single-center, long-term retrospective study of 150 post-craniotomy patients reported that a substantial proportion developed multi-site head, neck, or jaw pain years after surgery, with temporomandibular joint findings more common when the temporalis muscle was manipulated during the approach (as in pterional procedures). As a single-institution study, its findings should be regarded as a reported association rather than a generalizable population estimate. The retrosigmoid approach used for microvascular decompression is a different surgical corridor than the pterional approach discussed in that study, but the general principle — that craniotomy involves manipulation of pain-sensitive dura and surrounding tissue, and can be followed by chronic post-surgical pain — is relevant to post-operative monitoring and to distinguishing new jaw or facial symptoms after surgery from recurrence of the original trigeminal neuralgia.
When to see a specialist
Facial pain that is sudden, severe, shock-like, and triggered by light touch or chewing warrants evaluation by a neurologist or orofacial pain specialist, particularly if it does not respond to over-the-counter analgesics or standard dental treatment. If medication trials fail, referral for neurosurgical evaluation, including discussion of microvascular decompression, is a standard next step.
For referring providers
This surgical guide technology (PMID 42617496) is an intraoperative neuronavigation aid for retrosigmoid craniotomy, relevant primarily to neurosurgical colleagues performing MVD or other posterior fossa procedures. For dental sleep and orofacial pain practices, the practical takeaways are: (1) confirm trigeminal neuralgia diagnosis, including distinguishing incidental neurovascular contact from compression with morphological change on imaging, and exclude dental/TMJ mimics before referral; (2) counsel patients that surgical guide innovations at this stage are feasibility-level evidence from a single small cohort (n=10), not proof of improved outcomes; and (3) be aware that post-craniotomy patients may present later with craniomandibular pain unrelated to their original diagnosis, based on findings from a single-center study, warranting independent TMJ evaluation rather than assumption of trigeminal neuralgia recurrence.
Evaluation for facial pain and TMJ concerns, including coordination with neurology or neurosurgery when indicated, is available through this practice.
References
- PMID 42617496 — Retrosigmoid craniotomy surgical guide: The way forward for precise exposure of the transverse-sigmoid sinuses. Journal of Clinical Neuroscience, 2026.
- Effat KG, et al. Single-center retrospective study of long-term craniomandibular and head/neck pain following craniotomy (n=150).
